Hydroxyurea Gets DCGI Approval For Treatment Of Sickle Cell Anaemia

SCA is a common genetic disorder among Indians affecting red blood cells. It is transmitted by parents who carry a defective beta-globin gene without suffering themselves.

Hydroxyurea Gets DCGI Approval For Treatment Of Sickle Cell Anaemia

The Drugs Controller General of India (DCGI) has approved hydroxyurea for the treatment of Sickle Cell Anaemia.

The CSIR-Sickle Cell Anaemia (CSIR-SCA) Mission, coordinated by the CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB) with the help of Cipla, one of the manufacturers of hydroxyurea and with active support from CSIR-IIIM, had approached the DCGI for approval.